Legislative and regulatory shifts are moving quickly from Capitol Hill and state capitols into day-to-day operations. For health plans, third-party administrators (TPAs), and pharmacy benefit managers (PBMs), changes that once allowed long-range planning now demand near-term decisions across eligibility, utilization management (UM), and clinical staffing. Compliance depends as much on execution as on policy.

How H.R.1 Reframes Medicaid & Operations

The One Big Beautiful Bill Act (H.R.1) resets Medicaid. After years of leveraging Medicaid to expand access to coverage and care, the program is repositioned as a narrower safety net with greater emphasis on program integrity.

For health plans and PBMs, the operational impact is immediate. Tighter verification and documentation increases coverage churn and gap periods. Clinical reviews may hinge on coverage timing as well as clinical appropriateness, driving more continuity-of-care determinations, retroactive eligibility reviews, and appeals tied to administrative documentation.

While H.R.1 is federal policy, implementation is state-driven. Timelines, requirements, and enforcement will vary by state, increasing operational complexity for organizations in multiple states. Eligibility can no longer be treated as a front-end administrative step; it must be integrated into UM and appeals.

Operational priorities include:

• Embed eligibility verification into UM and appeal workflows
• Refresh medical necessity criteria to reflect state-by-state changes
• Prepare for increased appeal volume tied to eligibility and documentation disputes

State-Level Regulation Is Driving Day-to-Day Change

Alongside federal shifts, states continue to regulate the mechanics of UM, especially prior authorization (PA). Reforms increasingly targeted the use of artificial intelligence (AI), turnaround times, standardized definitions, reporting and transparency, and clinical oversight.

States are also beginning to regulate the use of AI in utilization management. Plans using algorithmic tools must be able to explain decision logic, show clinician involvement, and document consistent application criteria.

Common state trends include: 

• Streamlined prior authorization models and service exemptions
• Shorter turnaround time requirements 
• Expanded expectations for specialty-matched clinical review
• Increased reporting and transparency
• Electronic prior authorization with guardrails for AI use

These reforms reduce administrative burden if intake, routing, review logic, and documentation are redesigned to meet the new standards.

Impacts on Health Plan Clinical Operations

PA reform compresses timelines while raising documentation expectations. Added scrutiny of AI-supported reviews introduces requirements for audit trails, clinical accountability, and defensible application of criteria. All of this occurs amid ongoing staffing constraints.

Clinical operations cannot respond by simply adding headcount. The sustainable approach is to standardize routine reviews while directing complex cases and appeals to experienced clinicians. Operational workflows are as important as clinical accuracy.

Impacts on Pharmacy Operations

Pharmacy operations face a distinct set of pressures, driven by drug pricing policy and coverage expansion.

Beginning in 2026, changes affecting GLP-1 pricing, Medicare negotiation, and reimbursement models are expected to reshape cost and utilization patterns. PA criteria, step therapy requirements, and exception processes will need to evolve accordingly.

At the same time, coverage signals for select weight-loss indications are expanding. Broader access paired with tighter cost controls increases operational strain. When criteria are unclear, inconsistently applied, or poorly communicated — appeal volume rises quickly, followed by provider confusion and member dissatisfaction.

State-level PA reform increasingly applies to pharmacy as well. Turnaround time standards, reporting requirements, and transparency expectations increasingly mirror those on the medical side. Pharmacy workflows must meet these standards consistently with clear documentation, appropriate clinical oversight, and auditable decision paths. Data is essential as an operating tool to identify where criteria are working, where appeals overturn decisions, and where operational friction occurs.

Adapting Review Operations Without Adding Headcount

Regulatory change is colliding with workforce constraints. Budget pressure, clinical staffing shortages, and rising utilization make it unrealistic to “add more reviewers” for every new requirement.

The practical response is deliberate allocation of clinical effort. Routine, low-variability cases are increasingly handled through standardized, tech-enabled workflows. Complex cases, exceptions, and appeals are directed to experienced clinicians who can apply judgment where it matters most. Clear escalation paths and consistent documentation reduce rework while supporting compliance.

Prioritizing Compliance for 2026, 2027, and Beyond

As regulatory volume increases, prioritization is critical. Near-term focus should center on:

• Turnaround time performance where state standards drive complaint or audit risk
• Member notices and appeals so timelines and documentation align with updated requirements
• Eligibility-related reviews where mid-care coverage changes create avoidable appeals and continuity-of-care risk

Medicare Advantage may see regulatory stability in 2027, creating a narrow window in 2026 to harden eligibility processes, tighten UM workflows, and reduce operational friction before the next wave of reform. Beyond 2027, pressure is unlikely to ease as Medicaid enrollment is projected to decline while utilization remains elevated. At the same time, CMS has signaled further reforms tied to risk adjustment, quality measurement, and technology-enabled oversight.

From Policy Awareness to Operational Readiness

Policy change is inevitable, but operational readiness is a choice. The work now is building clinical and pharmacy operations that adapt quickly, remain compliant, and support sound clinical judgment without disrupting care, consistency, or clinical decision-making.

The post From Policy to Practice: What Today’s Regulatory Shifts Mean for Clinical and Pharmacy Operations appeared first on MRIoA.

The post From Policy to Practice: Translating New Regulations into Action for Payer and PBM Clinical Operations appeared first on MRIoA.

If your organization isn’t prepared, the risks are clear: fines, compliance penalties, reputational harm, and provider dissatisfaction. 

At MRIoA, our mission is to give health plans clarity and confidence in navigating these complex changes. Here’s a closer look at four states where new regulations are going into effect and what they mean for your business. 

Georgia – H.B. 197 (Effective Jan 1, 2026) 

What’s changing: Georgia requires insurers to make a good-faith effort for a pre-denial peer-to-peer review. That effort must include either a callback system, a telecommunications platform, or a public website to schedule callbacks. In addition, insurers must implement and maintain a program to reduce prior authorization requirements, with the first filing due July 1, 2026.  

• Georgia General Assembly – HB 197: https://www.legis.ga.gov/legislation/64277 

Why it matters: These requirements add new operational and reporting burdens. Failure to comply risks fines, member delays, and strained provider relationships. 

Takeaway: Don’t wait until the deadline. Begin building callback workflows now and assess how your PA program can be reduced without compromising compliance. 

Illinois – H.B. 4055 (Effective Jan 1, 2026) 

What’s changing: Illinois will restrict plans from requiring prior authorization for FDA-approved therapies for hereditary bleeding disorders more frequently than every six months, or for the length of the prescription, whichever is shorter.  

• Illinois General Assembly – HB4055: https://www.ilga.gov/legislation/billstatus.asp?DocNum=4055&GAID=19&GA=103&DocTypeID=HB&LegID=152792&SessionID=112 

Why it matters: This is not a full PA ban, but it requires significant adjustments to authorization logic and systems. Failure to comply risks penalties, reputational harm, and potential patient impact. 

Takeaway: Update your PA rules and test your systems now to avoid costly mistakes. 

Texas – H.B. 3812 & S.B. 815 (Effective Sept 1, 2025) 

What’s changing: H.B. 3812 requires that certain determinations be made by a Texas-licensed physician, who may not hold an administrative medicine license. 

• Texas Legislature – HB 3812: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=HB3812 

S.B. 815 prohibits utilization review agents from using automated decision systems to make adverse determinations. The law also grants the commissioner authority to audit UR agents’ practices.  

• Texas Legislature – SB 815: https://capitol.texas.gov/BillLookup/History.aspx?LegSess=88R&Bill=SB815 

Why it matters: Health plans must align physician oversight models with licensing requirements and ensure compliance processes can withstand audits. 

Takeaway: Evaluate your current utilization review oversight and ensure your staffing and governance models meet Texas’ new requirements. 

The Bottom Line 

These are not minor updates. They are business-impacting regulatory changes with real financial, operational, and reputational stakes. 

MRIoA provides the clinical expertise, regulatory guidance, and actionable insights that health plans, TPAs, and PBMs need to adapt quickly and with confidence. 

Join us for the Regulatory & Compliance Roundtable on October 2, 2025 to hear from experts, understand what these laws mean for your organization, and walk away with strategies to reduce risk and ensure compliance. 

View the Roundtable Recording

The post Is your Organization Ready for Fall 2025 State Regulatory Changes?  appeared first on MRIoA.

According to the American Medical Association, ten states passed significant prior authorization reforms in 2024, tightening turnaround times, mandating greater transparency, and easing administrative burdens. At the same time, nine states and the District of Columbia passed reforms in the prior year, and nearly 30 states are considering similar legislation now.  

This wave of legislation is fundamentally changing how health plans, TPAs, and PBMs will be evaluated and held accountable. Non-compliance is no longer measured only in fines, but in lost revenue, reputational damage, and competitive disadvantage.  

Why These Changes Matter to the C-Suite 

Revenue at Risk 
Fines, lawsuits, and contract losses can dwarf the cost of proactive compliance. Illinois’ new restrictions on prior authorization for hereditary bleeding disorder drugs require precise operational updates. A missed adjustment is not just a workflow error. It is a potential revenue and reputation crisis. 

Operational Disruption 
Georgia’s H.B. 197 mandates callback systems and PA-reduction programs. That means new infrastructure, new processes, and new reporting obligations. For executives, this translates into resourcing decisions and system investments that must be made quickly. 

Regulatory Scrutiny 
Texas’ new laws (S.B. 815 and H.B. 3812) create strict requirements for utilization review oversight and give regulators the authority to audit payer processes at any time. That puts executive accountability squarely in the spotlight. 

Competitive Differentiation 
New Jersey’s A.B. 1825 establishes step therapy exception requirements that will create winners and losers. Those who adapt quickly will maintain provider trust and member satisfaction. Those who lag risk being viewed as slow, opaque, and non-compliant. That is a costly brand position in a competitive market. 

What Executives Should Be Asking 

• Where is our greatest compliance risk exposure: financial, operational, or reputational? 
• Do we have the infrastructure to meet callback, exception, and reporting mandates across multiple states? 
• How are we monitoring and auditing utilization review processes to ensure readiness for regulator scrutiny? 
• Are we positioned to turn compliance into an advantage, not just an obligation? 

MRIoA’s Role: From Compliance Burden to Strategic Readiness 

For leadership, the question is not just “are we compliant?” It is “how do we make compliance an advantage?” 

MRIoA helps executives answer that question by delivering: 

• Regulatory Foresight – We track and interpret state-by-state changes before they become pain points, giving leadership the ability to plan strategically instead of reactively. 
• Operational Assurance – With the largest state-matched reviewer network in the nation, we ensure compliance requirements do not stall operations, disrupt provider relations, or inflate costs. 
• Business Intelligence – Our analytics surface where regulatory risk lives in your workflows, allowing you to redirect resources, reduce waste, and protect revenue. 

MRIoA does not just reduce the burden of compliance. We give executives the clarity and confidence to make faster, better, and more defensible business decisions. 

The Strategic Imperative 

The regulatory landscape is not slowing down. With dozens of states advancing new prior authorization reforms in 2024 and 2025, compliance is now a C-suite responsibility. It is no longer about avoiding penalties. It is about protecting revenue, sustaining trust, and creating competitive advantage. 

Watch MRIoA’s Regulatory & Compliance Roundtable from October 2, 2025. Gain insights into what these state laws mean for your organization and learn how to turn regulatory change into strategic readiness. 

Vide the Roundtable Recording

The post Compliance Is a Business Risk You Can’t Ignore  appeared first on MRIoA.

Watch an on-demand recording of MRIoA’s Fall 2025 Regulatory Roundtable to hear how these changes may impact your organization and what you can do now to prepare. This isn’t just another list of policy updates, it’s an actionable roadmap to compliance, clarity, and operational efficiency.

What You’ll Gain:

• A brief refresher of state-specific regulations taking effect in 2025 for Arkansas, Nebraska, Maryland, Oklahoma, Texas, Rhode Island, Maine, and Montana.
• A forward-looking preview of January 2026 requirements covering prior authorization transparency, medical necessity definitions, specialty match, and peer-to-peer protocols.
• Actionable strategies to align compliance with operational workflows and avoid costly fines, audits, and provider friction.
• Insight into MRIoA’s proven solutions designed to help payers stay compliant, reduce disruption, and adapt with confidence.

Featured State Highlights:

• Georgia (H.B. 197): Pre-denial peer-to-peer process including callback telecommunications, and PA reduction programs.
• Illinois (H.B. 4055): Elimination of prior authorizations for FDA-approved therapies for hereditary bleeding disorders.
• Preview of January 2026 requirements coming to Arizona, Colorado, Georgia, Illinois, Montana, Nevada, New Jersey, North Dakota, Virginia, and Wyoming

Why It Matters:

Healthcare faces one of the most complex regulatory landscapes in history. Organizations that act now can avoid costly fines, reputational damage, and strengthen compliance programs before new laws take effect.

Led by Aja Leichliter, Chief Compliance Officer at MRIoA, this session was designed for decision-makers who need clarity, not clutter.

The post Fall 2025 Regulatory Roundtable appeared first on MRIoA.